Compare Regeneron Pharmaceuticals Inc (REGN) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Raymond James Financial, Inc. — how do they compare? Regeneron Pharmaceuticals Inc trades at $653.5 (market cap $70.79B), while Raymond James Financial, Inc. trades at $167 (market cap $32.73B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.2× Raymond James Financial, Inc.'s market cap, and Raymond James Financial, Inc. pays the higher dividend (1.29%). Which is the better fit depends on your goals.
| REGN | RJF | |
|---|---|---|
Market Cap | $70.79B | $32.73B |
Sector | Health | Financials |
52-Week High | $812.27 | $176.43 |
52-Week Low | $545.46 | $140.89 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | 1.29% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
